Melatonin: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(outline, risks and safety, expand, tidy)
(ref, dose)
Line 16: Line 16:
==Costs and availability==
==Costs and availability==
In [[Canada]] and the [[United States]], melatonin is sold over-the-counter. In other countries, such as the [[United Kingdom]], it is only available with a prescription but may be legal to import for personal use.
In [[Canada]] and the [[United States]], melatonin is sold over-the-counter. In other countries, such as the [[United Kingdom]], it is only available with a prescription but may be legal to import for personal use.
==Dosage==
Typical doseage for melatonin is 1-5mg per night.<ref name="emc" />


==Risks and safety ==
==Risks and safety ==
Melatonin has not need studied in people with [[autoimmune disorder|autoimmune disease]]<ref name="emc">https://emc-prod-ukwest-wa.azurewebsites.net/emc/product/10024/smpc</ref>, however ME/CFS is not classed as an autoimmune disease at present despite the [[:Category:Immune signs and symptoms|immune symptoms]].<ref name="ICC2011primer">{{citation| last1 = Carruthers | first1 = BM | authorlink1 = Bruce Carruthers| last2 = van de Sande | first2 = MI | authorlink2 = Marjorie van de Sande
Melatonin has not need studied in people with [[autoimmune disorder|autoimmune disease]]<ref name="emc">{{Cite web |title =Slenyto 5 mg prolonged-release tablets|website=electronic medicines compendium |access-date =Mar 4, 2021|url=https://emc-prod-ukwest-wa.azurewebsites.net/emc/product/10024/smpc}}</ref>, however ME/CFS is not classed as an autoimmune disease at present despite the [[:Category:Immune signs and symptoms|immune symptoms]].<ref name="ICC2011primer">{{citation| last1 = Carruthers | first1 = BM | authorlink1 = Bruce Carruthers| last2 = van de Sande | first2 = MI | authorlink2 = Marjorie van de Sande
| last3 = De Meirleir | first3 = KL | authorlink3 = Kenny de Meirleir
| last3 = De Meirleir | first3 = KL | authorlink3 = Kenny de Meirleir
| last4 = Klimas | first4 = NG | authorlink4 = Nancy Klimas| last5 = Broderick | first5 = G | authorlink5 = Gordon Broderick
| last4 = Klimas | first4 = NG | authorlink4 = Nancy Klimas| last5 = Broderick | first5 = G | authorlink5 = Gordon Broderick
Line 38: Line 41:
| date = 2012| isbn = 978-0-9739335-3-6
| date = 2012| isbn = 978-0-9739335-3-6
| url = http://www.investinme.org/Documents/Guidelines/Myalgic%20Encephalomyelitis%20International%20Consensus%20Primer%20-2012-11-26.pdf
| url = http://www.investinme.org/Documents/Guidelines/Myalgic%20Encephalomyelitis%20International%20Consensus%20Primer%20-2012-11-26.pdf
}}</ref><ref name="ICD11">{{cite web|title=ICD-11 - Mortality and Morbidity Statistics|url=https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f569175314|last=World Health Organization|first=|authorlink=World Health Organization|date=2020|website=icd.who.int|url-status=|archive-url=|archive-date=|accessdate=20 May 2020|quote=Diseases of the nervous system}}</ref><ref name="CDC-IOM-SEIDcriteria">{{Cite web|url=https://www.cdc.gov/me-cfs/healthcare-providers/diagnosis/iom-2015-diagnostic-criteria.html|title=IOM 2015 Diagnostic Criteria {{!}} Myalgic Encephalomyelitis/Chronic Fatigue Syndrome|website=[[Centers for Disease Control|date=Jan 27, 2021|access-date =2021-02-25}}</ref>
}}</ref><ref name="ICD11">{{cite web|title=ICD-11 - Mortality and Morbidity Statistics|url=https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f569175314|last=World Health Organization|first=|authorlink=World Health Organization|date=2020|website=icd.who.int|url-status=|archive-url=|archive-date=|access-date=20 May 2020|quote=Diseases of the nervous system}}</ref><ref name="CDC-IOM-SEIDcriteria">{{Cite web|url=https://www.cdc.gov/me-cfs/healthcare-providers/diagnosis/iom-2015-diagnostic-criteria.html|title=IOM 2015 Diagnostic Criteria {{!}} Myalgic Encephalomyelitis/Chronic Fatigue Syndrome|website=[[Centers for Disease Control]]|date=Jan 27, 2021|access-date =2021-02-25}}</ref>


==Notable studies==
==Notable studies==

Revision as of 13:18, March 4, 2021

Two round white melatonin tablets next to a bottle of melatonin tablets.

Melatonin, also sold under the brand name Slenyto, is a hormone produced in the pineal gland which regulates sleep and wakefulness.[1][2] It is involved in the synchronization of circadian rhythms, including sleep-wake timing, blood pressure and body temperature regulation, cardiovascular efficiency and muscle strength, and many others.[3][4]

Theory[edit | edit source]

Many of melatonin's biological effects are produced through activation of melatonin receptors,[5] while others are due to its role as an antioxidant,[1] with a particular role in the protection of nuclear and mitochondrial DNA.[6]

Melatonin supplements or medication are commonly used for helping people get to sleep or stay asleep.[7][2]

ME/CFS[edit | edit source]

Evidence[edit | edit source]

As a medicine, it is used for the treatment of insomnia, however, scientific evidence is insufficient to demonstrate a benefit in this area.[8] Melatonin is also used for sleep dysfunction.

As a medicine, some forms of melatonin are licensed for use for Insomnia or sleep in children with ADHD.[2]

Costs and availability[edit | edit source]

In Canada and the United States, melatonin is sold over-the-counter. In other countries, such as the United Kingdom, it is only available with a prescription but may be legal to import for personal use.

Dosage[edit | edit source]

Typical doseage for melatonin is 1-5mg per night.[2]

Risks and safety[edit | edit source]

Melatonin has not need studied in people with autoimmune disease[2], however ME/CFS is not classed as an autoimmune disease at present despite the immune symptoms.[9][10][11]

Notable studies[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 Hardeland R (July 2005), "Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance", Endocrine, 27 (2): 119–30, doi:10.1385/ENDO:27:2:119, PMID 16217125
  2. 2.0 2.1 2.2 2.3 2.4 "Slenyto 5 mg prolonged-release tablets". electronic medicines compendium. Retrieved March 4, 2021.
  3. Altun A, Ugur-Altun B (May 2007), "Melatonin: therapeutic and clinical utilization", Int. J. Clin. Pract., 61 (5): 835–45, doi:10.1111/j.1742-1241.2006.01191.x, PMID 17298593
  4. Hardeland R, Pandi-Perumal SR, Cardinali DP (March 2006), "Melatonin", The International Journal of Biochemistry & Cell Biology, 38 (3): 313–6, doi:10.1016/j.biocel.2005.08.020, PMID 16219483
  5. Boutin JA, Audinot V, Ferry G, Delagrange P (August 2005), "Molecular tools to study melatonin pathways and actions", Trends Pharmacol. Sci., 26 (8): 412–19, doi:10.1016/j.tips.2005.06.006, PMID 15992934
  6. Reiter RJ, Acuña-Castroviejo D, Tan DX, Burkhardt S (June 2001), "Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system", Ann. N. Y. Acad. Sci., 939: 200–15, doi:10.1111/j.1749-6632.2001.tb03627.x, PMID 11462772
  7. "Melatonin". drugs.com. Retrieved March 4, 2021.
  8. Brasure M, MacDonald R, Fuchs E, Olson CM, Carlyle M, Diem S, Koffel E, Khawaja IS, Ouellette J, Butler M, Kane RL, Wilt TJ (December 2015), Management of Insomnia Disorder [Internet], PMID 26844312
  9. Carruthers, BM; van de Sande, MI; De Meirleir, KL; Klimas, NG; Broderick, G; Mitchell, T; Staines, D; Powles, ACP; Speight, N; Vallings, R; Bateman, L; Bell, DS; Carlo-Stella, N; Chia, J; Darragh, A; Gerken, A; Jo, D; Lewis, DP; Light, AR; Light, KC; Marshall-Gradisnik, S; McLaren-Howard, J; Mena, I; Miwa, K; Murovska, M; Stevens, SR (2012), Myalgic encephalomyelitis: Adult & Paediatric: International Consensus Primer for Medical Practitioners (PDF), ISBN 978-0-9739335-3-6
  10. World Health Organization (2020). "ICD-11 - Mortality and Morbidity Statistics". icd.who.int. Retrieved May 20, 2020. Diseases of the nervous system
  11. "IOM 2015 Diagnostic Criteria | Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Centers for Disease Control. January 27, 2021. Retrieved February 25, 2021.
  12. Williams, G.; Pirmohamed, J.; Minors, D.; Waterhouse, J.; Buchan, I.; Arendt, J.; Edwards, R. H. (July 1996), "Dissociation of body-temperature and melatonin secretion circadian rhythms in patients with chronic fatigue syndrome", Clinical Physiology (Oxford, England), 16 (4): 327–337, ISSN 0144-5979, PMID 8842569
  13. Adamczyk-Sowa, M.; Sowa, P.; Adamczyk, J.; Niedziela, N.; Misiolek, H.; Owczarek, M.; Zwirska-Korczala, K. (April 2016), "Effect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone", Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society, 67 (2): 235–242, ISSN 1899-1505, PMID 27226183